EA201892185A1 - METHOD FOR SELECTION OF RECOMBINANT PROTEINS WITH HIGH CONTENT M6P - Google Patents

METHOD FOR SELECTION OF RECOMBINANT PROTEINS WITH HIGH CONTENT M6P

Info

Publication number
EA201892185A1
EA201892185A1 EA201892185A EA201892185A EA201892185A1 EA 201892185 A1 EA201892185 A1 EA 201892185A1 EA 201892185 A EA201892185 A EA 201892185A EA 201892185 A EA201892185 A EA 201892185A EA 201892185 A1 EA201892185 A1 EA 201892185A1
Authority
EA
Eurasian Patent Office
Prior art keywords
high content
selection
recombinant proteins
recombinant human
human lysosomal
Prior art date
Application number
EA201892185A
Other languages
Russian (ru)
Other versions
EA039750B1 (en
Inventor
Хун В. До
Расселл Готшалль
Original Assignee
Амикус Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Амикус Терапьютикс, Инк. filed Critical Амикус Терапьютикс, Инк.
Priority claimed from US15/473,994 external-priority patent/US10227577B2/en
Publication of EA201892185A1 publication Critical patent/EA201892185A1/en
Publication of EA039750B1 publication Critical patent/EA039750B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Описаны способы получения, захвата и очистки рекомбинантных лизосомных белков человека. Такие рекомбинантные лизосомные белки человека могут иметь высокое содержание остатков маннозо-6-фосфата. Также описаны фармацевтические композиции, содержащие такие рекомбинантные лизосомные белки человека, а также способы лечения и пути применения таких рекомбинантных лизосомных белков человека.Methods for the preparation, capture and purification of recombinant human lysosomal proteins are described. Such recombinant human lysosomal proteins may have a high content of mannose-6-phosphate residues. Also described are pharmaceutical compositions containing such recombinant human lysosomal proteins, as well as methods of treatment and methods of using such recombinant human lysosomal proteins.

EA201892185A 2017-03-30 2017-03-30 Method for selection of high m6p recombinant proteins EA039750B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/473,994 US10227577B2 (en) 2016-03-30 2017-03-30 Method for selection of high M6P recombinant proteins
PCT/US2017/024981 WO2017173059A1 (en) 2016-03-30 2017-03-30 Method for selection of high m6p recombinant proteins

Publications (2)

Publication Number Publication Date
EA201892185A1 true EA201892185A1 (en) 2019-07-31
EA039750B1 EA039750B1 (en) 2022-03-10

Family

ID=67399668

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201892185A EA039750B1 (en) 2017-03-30 2017-03-30 Method for selection of high m6p recombinant proteins
EA202290114A EA202290114A1 (en) 2017-03-30 2017-03-30 METHOD FOR SELECTION OF RECOMBINANT PROTEINS WITH HIGH M6P CONTENT

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA202290114A EA202290114A1 (en) 2017-03-30 2017-03-30 METHOD FOR SELECTION OF RECOMBINANT PROTEINS WITH HIGH M6P CONTENT

Country Status (1)

Country Link
EA (2) EA039750B1 (en)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020073438A1 (en) * 1995-08-02 2002-06-13 Reuser Arnold J. Methods of purifying human acid alpha-glucosidase
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
JP2007523648A (en) * 2004-02-06 2007-08-23 バイオマリン ファーマシューティカル インコーポレイテッド Highly phosphorylated lysosomal enzyme preparations and their use
KR20080025373A (en) * 2005-05-17 2008-03-20 아미쿠스 세라퓨틱스, 인코포레이티드 A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
EP2946785B1 (en) * 2008-02-12 2018-10-24 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
WO2011039634A2 (en) * 2009-09-29 2011-04-07 Universiteit Gent Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose
CA2812870C (en) * 2010-09-29 2020-06-09 Oxyrane Uk Limited Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated n-glycans and methods of facilitating mammalian cellular uptake of glycoproteins
CN104379162B (en) * 2012-03-15 2017-03-15 奥克西雷恩英国有限公司 For treating method and the material of fluffy Pei Shi diseases
AU2015325028B2 (en) * 2014-09-30 2022-02-24 Amicus Therapeutics, Inc. Highly potent acid alpha-glucosidase with enhanced carbohydrates

Also Published As

Publication number Publication date
EA202290114A1 (en) 2022-03-29
EA039750B1 (en) 2022-03-10

Similar Documents

Publication Publication Date Title
MX2022014532A (en) Method for selection of high m6p recombinant proteins.
EA201390676A1 (en) VACCINES CONTAINING NON-SPECIFIC NUCLEOSIDE HYDROLASE POLYPEPTIDES AND STEROL 24-C-Methyltransferase (SMT), for the treatment and diagnosis of leishmaniasis
WO2017081211A3 (en) Antigen-binding polypeptides directed against cd38
EA201890145A1 (en) ANTIBODIES TO FACTOR XI AND METHODS OF THEIR APPLICATION
EA201391170A1 (en) THERAPEUTIC MEANS BASED ON YEAST FOR THE TREATMENT OF CHRONIC HEPATITIS B
EA201891399A1 (en) BIPIRAZOLE DERIVATIVES, SUITABLE FOR THE TREATMENT OF AUTOIMMUNE DISEASES
EA201390772A1 (en) NEW SALTS AND POLYMORPHIC FORMS OF AFATINIBA
EA201992083A1 (en) SOMATOSTATIN MODULATORS AND THEIR APPLICATION
EA201391515A1 (en) INACTIVATED DENGE VIRUS VACCINE
EA201692279A1 (en) METHOD FOR REDUCING IMMUNOGENIC PROTEIN AND PEPTIDE
EA201991029A1 (en) MAGL INHIBITORS
EA201892225A1 (en) ANTIBODIES TO THE COMPLEX Bb FACTOR AND THEIR APPLICATION
MX2019004487A (en) Methods and compositions for the treatment of fabry disease.
EA202191175A1 (en) CYSTEINE-DESIGNED ANTIBODY-DRUG CONJUGATES CONTAINING PEPTIDE-CONTAINING LINKERS
MX2020005555A (en) Tau peptide immunogen constructs.
EA201490032A1 (en) LYOPHYLIZED PREPARATIONS FGF-18
EA201991951A1 (en) LOW-VISCOUS HIGH-CONCENTRATED COMPOSITIONS BASED ON EVOLOCUMABA AND METHODS FOR PRODUCING THEM
EA201990998A1 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS FOR PRODUCING THEM
EA202191515A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING APIXABAN
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
EA201492059A1 (en) SOLID FORMS OF FIDAXOMYCINE AND METHODS FOR THEIR RECEPTION
PH12020551618A1 (en) Erenumab compositions and uses thereof
EA202191403A1 (en) COMPOSITION WITH HIGH PROTEIN CONCENTRATION
EA201892185A1 (en) METHOD FOR SELECTION OF RECOMBINANT PROTEINS WITH HIGH CONTENT M6P
EA201691603A1 (en) SUGAR DERIVATIVES CONTAINING SERO-CONTAINING FRAGMENTS, METHODS OF THEIR RECEIVING AND METHODS OF THEIR APPLICATION FOR THE TREATMENT OF MPS IIIC